---
schema_version: "secwatch.filing_event.v1"
accession: "0001619856-24-000068"
form_type: "8-K"
ticker: "CRBU"
cik: "0001619856"
company_name: "Caribou Biosciences, Inc."
filed_at: "2024-08-12T23:59:59+00:00"
generated_at: "2026-05-31T10:03:30.935441+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Caribou Biosciences appoints Tina Albertson, MD PhD, as Chief Medical Officer

## Summary
- Dr. Albertson brings 15 years of experience in cellular therapy development, most recently as CMO at Lyell Immunopharma.
- At Juno Therapeutics (BMS), she led global development of BREYANZI from IND to BLA filing and FDA approval.
- She will oversee clinical, regulatory, and medical affairs for Caribou's four CAR-T cell therapy programs.
- Dr. Albertson reports to CEO Rachel Haurwitz and will drive allogeneic CAR-T development in hematologic and autoimmune diseases.

## SEC filing metadata
- accession: 0001619856-24-000068
- form_type: 8-K
- ticker: CRBU
- cik: 0001619856
- company_name: Caribou Biosciences, Inc.
- filed_at: 2024-08-12T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1619856/000161985624000068/0001619856-24-000068-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1619856/000161985624000068/crbu-20240812.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001619856-24-000068
- JSON: https://secwatch.observer/filing/0001619856-24-000068.json
- Plain text: https://secwatch.observer/filing/0001619856-24-000068.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.